Current Opinion in Urology最新文献_第3页

What's in a name? Why differentiation between biochemical recurrence and metastatic prostate cancer matters. 名字里有什么？为什么区分生化复发和转移性前列腺癌很重要。

IF 2.2 3区医学

Current Opinion in Urology Pub Date : 2025-09-01 Epub Date: 2025-07-07 DOI: 10.1097/MOU.0000000000001317

Anael S Rizzo, Pratik Kanabur, Adam B Weiner

{"title":"What's in a name? Why differentiation between biochemical recurrence and metastatic prostate cancer matters.","authors":"Anael S Rizzo, Pratik Kanabur, Adam B Weiner","doi":"10.1097/MOU.0000000000001317","DOIUrl":"10.1097/MOU.0000000000001317","url":null,"abstract":"Purpose of review: The natural history of biochemical recurrence (BCR) is highly variable, complicating the distinction between BCR and metastasis. A targeted approach to risk stratifying disease progression is needed. This review proposes a 'framework,' that categorizes disease progression into five distinct groups: low-risk BCR, high-risk BCR, oligometastatic disease, low-volume metastatic disease, and high-volume metastatic disease. Each group is defined by clinicopathological and molecular features, along with targeted treatment strategies to tailor therapy and optimize disease management.Recent findings: Recent clinical trials and updates to guidelines have focused on treatment intensification and early identification of patients at risk for recurrence. In addition, the utilization of molecular imaging and implementation of metastasis directed therapy has led to a change in the conventions of recurrence and metastasis. Therefore, the patients with BCR or metastatic disease require a more individualized and multimodal treatment for their prostate cancer.Summary: Distinguishing BCR from metastatic disease has important implications. It offers ways to avoid unnecessary treatment in patients who are less likely to progress and helps identify those who are more likely to benefit from earlier or more aggressive interventions.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"535-540"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood- and urine-based biomarkers for the detection of clinically significant prostate cancer: a contemporary review. 基于血液和尿液的生物标志物检测临床意义重大的前列腺癌：当代回顾。

IF 2.2 3区医学

Current Opinion in Urology Pub Date : 2025-09-01 Epub Date: 2025-06-27 DOI: 10.1097/MOU.0000000000001308

Keavash D Assani, Janene M Pierce, Lan Anh Galloway, Jeffrey J Tosoian

{"title":"Blood- and urine-based biomarkers for the detection of clinically significant prostate cancer: a contemporary review.","authors":"Keavash D Assani, Janene M Pierce, Lan Anh Galloway, Jeffrey J Tosoian","doi":"10.1097/MOU.0000000000001308","DOIUrl":"10.1097/MOU.0000000000001308","url":null,"abstract":"Purpose of review: Prostate cancer (PCa) is the most common malignancy in men. While prostate-specific antigen (PSA) screening aids early detection, its low specificity leads to unnecessary biopsies and overdiagnosis of low-grade cancers. Blood- and urine-based biomarkers are proposed by clinical guidelines to better identify patients with elevated PSA that can safely avoid more intensive testing (e.g. imaging, biopsy). The current article aims to provide clinicians and researchers with a contemporary assessment of prostate cancer biomarker tests.Recent findings: This review focused on prebiopsy blood- and urine-based biomarker tests that are commercially-available and included in clinical guidelines. A systematic search identified 955 studies, of which 14 were published in the past 18 months (July 2023-January 2025) and reported performance metrics for clinically significant PCa (csPCa, defined as grade group ≥2). The literature revealed that blood- [Prostate Health Index (PHI), 4Kscore, and IsoPSA] and urine-based tests [SelectMDx, ExoDx IntelliScore (EPI), and MyProstateScore (MPS, MPS2)] maintained high sensitivity for csPCa while significantly reducing unnecessary biopsies performed relative to PSA-based testing. Furthermore, available data suggest that biomarkers can inform the need for biopsy in patients with equivocal (PI-RADS 3) mpMRI.Summary: Commercially-available, noninvasive biomarker tests consistently outperformed PSA and PSA-based risk calculators for detection of csPCa. Clinical use of these tests appears to substantially reduce the proportion of unnecessary biopsies performed, while maintaining detection of the vast majority of significant cancers.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"590-596"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in radiotherapy for genitourinary cancers. 泌尿生殖系统癌放射治疗的进展。

IF 2.2 3区医学

Current Opinion in Urology Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1097/MOU.0000000000001320

Marcin Miszczyk

引用次数: 0

Does surgical removal of kidney stones help prevent the recurrence of urinary tract infections? A systematic review. 手术切除肾结石是否有助于预防尿路感染的复发？系统回顾。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-22 DOI: 10.1097/MOU.0000000000001328

Michelle Yuki Man, Bhaskar Somani, Amelia Pietropaolo

{"title":"Does surgical removal of kidney stones help prevent the recurrence of urinary tract infections? A systematic review.","authors":"Michelle Yuki Man, Bhaskar Somani, Amelia Pietropaolo","doi":"10.1097/MOU.0000000000001328","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001328","url":null,"abstract":"Purpose of review: Kidney stones disease (KSD) and urinary tract infections (UTIs) can be associated and reciprocally causal. Aim of this study is to understand the association between stone-free rate and infection clearance or recurrence after surgery.Recent findings: Studies are suggesting that removing stones may help to prevent UTIs. A systematic review was done to look at the relationship between UTIs and kidney stones and to find out whether stone removal surgery can help to reduce UTIs. The systematic review as done as per PRISMA checklist and three databases (Ovid MEDLINE, Cochrane Library and Embase) were searched for articles reporting on patients with recurrent UTIs and kidney stone surgery. All studies in English language were included with 1009 articles identified between 2000 and 2024.In the 10 studies finally selected, 1731 stones procedures were performed. Nine studies demonstrated a significant correlation between stone clearance and resolution of urinary tract infections.Summary: Surgical management of kidney stones appears to play a significant role in reducing UTI recurrence among patients with recurrent infections. Achieving stone clearance is associated with a higher likelihood of infection resolution and prolongation of infection-free intervals postoperatively.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Technological innovation and revolution with single-use digital flexible ureteroscopes: a review from section of EAU Endourology. 一次性数字化柔性输尿管镜的技术革新与革命：来自EAU输尿管学分会的综述。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-01-07 DOI: 10.1097/MOU.0000000000001260

Ali Talyshinskii, Lazaros Tzelves, Eugenio Ventimiglia, Steffi Kar Kai Yuen, Vineet Gauhar, Oliver Traxer, Bhaskar Somani

{"title":"Technological innovation and revolution with single-use digital flexible ureteroscopes: a review from section of EAU Endourology.","authors":"Ali Talyshinskii, Lazaros Tzelves, Eugenio Ventimiglia, Steffi Kar Kai Yuen, Vineet Gauhar, Oliver Traxer, Bhaskar Somani","doi":"10.1097/MOU.0000000000001260","DOIUrl":"10.1097/MOU.0000000000001260","url":null,"abstract":"Purpose of review: Numerous scope-related innovations have taken place in the field of endourology. The presented analytical review is aimed at studying the technical innovations of the single-use digital flexible ureteroscopes. In November 2024, a comprehensive search was done for information on latest disposable flexible digital ureteroscopes, as well as their various unique characteristics. A thorough examination was conducted for image qualities; sizes and channels; and deflection capabilities. Furthermore, supplementary features about the latest advances were assigned to a separate group including 'Unique' solutions. Using the last search query, various innovations in flexible ureteroscopy in general were also searched and sorted into appropriate groups.Recent findings: Modern single-use flexible digital ureteroscopes are characterized by advanced technologies for transmitting light and images, miniaturization, as well as by a number of unique solutions that were previously characteristic only of semi-rigid or fiberoptic endoscopes. These include features such as integrated buttons for data recording, self-locking mechanism, separate ports, rotating shaft, direct-in-scope suction, pressure monitoring, enhanced tip control and customizable settings.Summary: Since their introduction in urology, endoscopes have undergone many changes, as illustrated by the example of single-use flexible digital ureteroscopes. The imaging quality has improved, the dimensions of both the distal tip and shaft have decreased, with over 15 manufactures producing and distributing these scopes. A lot of new additional new features are likely to enhance the efficacy and safety of ureteroscopic procedures.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"360-367"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing clinical risk stratification of localized prostate cancer. 优化局限性前列腺癌的临床风险分层。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-05-02 DOI: 10.1097/MOU.0000000000001294

Vincent J Gnanapragasam

{"title":"Optimizing clinical risk stratification of localized prostate cancer.","authors":"Vincent J Gnanapragasam","doi":"10.1097/MOU.0000000000001294","DOIUrl":"10.1097/MOU.0000000000001294","url":null,"abstract":"Purpose of review: To review the current risk and prognostic stratification systems in localised prostate cancer. To explore some of the most promising adjuncts to clinical models and what the evidence has shown regarding their value.Recent findings: There are many new biomarker-based models seeking to improve, optimise or replace clinical models. There are promising data on the value of MRI, radiomics, genomic classifiers and most recently artificial intelligence tools in refining stratification. Despite the extensive literature however, there remains uncertainty on where in pathways they can provide the most benefit and whether a biomarker is most useful for prognosis or predictive use. Comparisons studies have also often overlooked the fact that clinical models have themselves evolved and the context of the baseline used in biomarker studies that have shown superiority have to be considered.Summary: For new biomarkers to be included in stratification models, well designed prospective clinical trials are needed. Until then, there needs to be caution in interpretation of their use for day-to-day decision making. It is critical that users balance any purported incremental value against the performance of the latest clinical classification and multivariate models especially as the latter are cost free and widely available.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"426-431"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

En bloc resection of large bladder tumor: is it feasible and reasonable? 膀胱大肿瘤整体切除是否可行、合理？

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-01-20 DOI: 10.1097/MOU.0000000000001265

Diana Babaevskaya, Andrey Morozov, Eddie Fridman, Larisa Tsoy, Shahrokh F Shariat, Yossef Molchanov, Maxim Yakimov, Eva Compérat, Thomas R W Herrmann, Dmitry Enikeev

{"title":"En bloc resection of large bladder tumor: is it feasible and reasonable?","authors":"Diana Babaevskaya, Andrey Morozov, Eddie Fridman, Larisa Tsoy, Shahrokh F Shariat, Yossef Molchanov, Maxim Yakimov, Eva Compérat, Thomas R W Herrmann, Dmitry Enikeev","doi":"10.1097/MOU.0000000000001265","DOIUrl":"10.1097/MOU.0000000000001265","url":null,"abstract":"Purpose of review: Transurethral resection of bladder tumor (TURBT) remains the basis of bladder tumor diagnosis and an effective means of treating nonmuscle invasive bladder cancer (NMIBC). There are several limitations to this procedure: TURBT may cause free floating of malignant cells in the bladder and as a result re-implantation and early recurrence. Also, it does not allow the pathologist to define the correct spatial orientation of the specimen. The development of en bloc resection of bladder tumor (ERBT) has helped overcome the abovementioned key disadvantages of TURBT. However, many urologists doubt whether this approach is feasible for treating larger tumors.Recent findings: In this review, it is shown that ERBT of large bladder tumor (>3 cm) is in fact a feasible and well tolerated method. Although there is a lack of comparative data proving its advantages over TURBT, en bloc in large tumor seems to result in better local cancer control (due to higher prevalence of detrusor specimen, lower need for re-TURBT), lower rate of relapse outside the resection area (due to lower risk of tumor cells circulation), and higher quality of pathology specimen.Summary: Despite the skepticism of some surgeons, potential difficulties caused by larger tumor size may be overcome easily, and most agree that tumor size should not limit the implementation of the method in their daily practice.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"385-389"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity and BMI score as risk factors for urolithiasis: a systematic review over 30 years. 肥胖和BMI评分作为尿石症的危险因素：一项超过30年的系统回顾

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-05-05 DOI: 10.1097/MOU.0000000000001298

Megha Garg, Philip Joseph, Hans Johnson, Joseph Vayalil Lawrence, Bhaskar Somani, Bhavan Prasad Rai, Joe Philip

{"title":"Obesity and BMI score as risk factors for urolithiasis: a systematic review over 30 years.","authors":"Megha Garg, Philip Joseph, Hans Johnson, Joseph Vayalil Lawrence, Bhaskar Somani, Bhavan Prasad Rai, Joe Philip","doi":"10.1097/MOU.0000000000001298","DOIUrl":"10.1097/MOU.0000000000001298","url":null,"abstract":"Purpose of review: To examine association between high BMI, obesity, and kidney stone disease (KSD). For this, systematic review of empirical studies was performed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) guidelines. Cochrane Library, EMBASE, MEDLINE, CINAHL, AMED, Emcare, Clinicaltrials.gov, and WHO ICTRP were searched for English language population-based studies published from inception to October 2024, including adults aged at least 18 years reporting on high BMI, obesity and overweight, with incidence of KSD.Recent findings: The search identified 943 records, of which 15 relevant articles with 97 645 participants and 17 158 cases in total were enrolled in the narrative synthesis. A high heterogeneity and imbalance were observed among baseline distribution of cohorts in most studies. Thirteen studies provided comparative data on stone occurrence in obese and nonobese participants, and on per-patient analysis, three studies demonstrated a lower risk (RR < 1; 95% CI: 0.78-1.03), four studies a higher risk (RR>1; 95% CI: 0.77-2.32), and six studies depicted similar risk (RR = 1; 95% CI: 0.94-1.06) of stone occurrence between the two cohorts.Summary: Evidence in this study suggests an association between high BMI, being overweight, obesity, and increased risk of developing kidney stone disease. In the context of optimizing treatment, KSD should be considered a metabolic disease, with treatment to include dietary regimes, exercise intervention alongside pharmacotherapy to help reduce renal stone disease recurrence risk, alongside managing associated chronic diseases such as hypertension, type 2 diabetes mellitus, and coronary artery disease.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"338-346"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salvage treatment of local recurrence following radical and partial nephrectomy. 根治性和部分性肾切除术后局部复发的抢救治疗。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-04-04 DOI: 10.1097/MOU.0000000000001286

Davide Perri, Carlotta Palumbo, Alessandro Volpe

{"title":"Salvage treatment of local recurrence following radical and partial nephrectomy.","authors":"Davide Perri, Carlotta Palumbo, Alessandro Volpe","doi":"10.1097/MOU.0000000000001286","DOIUrl":"10.1097/MOU.0000000000001286","url":null,"abstract":"Purpose of review: Standardized definition of local recurrence after radical or partial nephrectomy is still lacking. Due to its rarity, data on natural history, oncological outcomes and prognostic factors are scarce and specific treatment recommendations cannot be made.Recent findings: Surgery is still the preferred option to treat a local recurrence of renal cell carcinoma, with favorable survival outcomes. However, nonsurgical options like thermal ablation techniques may represent a valid alternative mainly in patients where a nephron-sparing treatment is imperative. Systemic therapy seems to have a limited role in this setting.Summary: According to available data, surgical excision of local recurrence should be attempted whenever feasible. Alternatively, thermal ablation represents a reliable and repeatable option after partial nephrectomy, with low complication rate and good oncologic outcomes. However, the evidence comes mainly from limited, heterogeneous case series. Further high-quality studies are needed to properly define the most appropriate for each individual patient.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"481-488"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxicities of radioligand and radioisotope therapy in prostate cancer: a systematic review and meta-analysis. 放射配体和放射性同位素治疗前列腺癌的毒性：系统回顾和荟萃分析。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-05-05 DOI: 10.1097/MOU.0000000000001300

David Ventura, Benjamin Noto, Nadir Rodriguez Jauregui, Wolfgang Roll, Kambiz Rahbar

{"title":"Toxicities of radioligand and radioisotope therapy in prostate cancer: a systematic review and meta-analysis.","authors":"David Ventura, Benjamin Noto, Nadir Rodriguez Jauregui, Wolfgang Roll, Kambiz Rahbar","doi":"10.1097/MOU.0000000000001300","DOIUrl":"10.1097/MOU.0000000000001300","url":null,"abstract":"Purpose of review: This systematic review and meta-analysis investigate the toxicities of radioligand and radioisotope therapies - [ 177 Lu]lutetium-prostate-specific membrane antigen (PSMA) (Lu-PSMA), [ 225 Ac]actinium-PSMA (Ac-PSMA), and [ 223 Ra]radium-dichloride (223-Radium) - in metastatic prostate cancer. While previous studies have explored this topic, most failed to differentiate between treatment-emergent adverse events (TEAEs) and preexisting conditions, leading to inflated toxicity rates. By focusing exclusively on TEAEs, this study provides a more accurate and clinically relevant assessment.Recent findings: This meta-analysis of 65 studies including 8706 patients identified haematotoxicities as the most frequent TEAEs across all therapies, affecting 10-20% of patients. Fatigue is a common nonhematologic adverse event in all treatments. Low grade xerostomia is specifically associated with Lu-PSMA and Ac-PSMA therapies, occurring in 30% and 84% of patients, respectively, while 223-Radium is uniquely linked to an increased fracture risk. Severe toxicities (Common Terminology Criteria for Adverse Events ≥ 3) are rare across all therapies. By clearly distinguishing TEAEs from baseline conditions, this study addresses a gap in the existing literature.Summary: Severe TEAEs are uncommon across Lu-PSMA, Ac-PSMA, and 223-Radium therapies. Still, monitoring and managing specific toxicities to optimize the safety and tolerability of these therapies in clinical practice is mandatory, especially concerning xerostomia in Ac-PSMA therapy.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"472-480"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0